Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Alzheimer's treatment has proven to not only slow down but also reverse cognition degeneration in Alzheimer's patients leaving the door open for early approval. Concerns existed on a possible placebo effect but recently presented 12-month data put those concerns aside and furthermore opened the door for FDA fast track approval or breakthrough designation.

Cassava Sciences' Simufilam Could Be Approved Before The End Of 2022

New York, New York--(Newsfile Corp. - September 28, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...

SAVA INVESTOR LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

RADNOR, Pa., Sept. 28, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces to investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ:  SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").

SAVA EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Cassava Sciences, Inc.

San Francisco, California--(Newsfile Corp. - September 28, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVAContact An Attorney Now: SAVA@hbsslaw.com844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning Casava's Alz

SAVA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Lawsuit Filed

Last month we discussed that Cassava Sciences stock, based on historical performance, is likely to see lower levels after it plunged 24% in a week following a citizen petition filed to halt the trials for Simufilam - Cassava's promising candidate for the treatment of Alzheimer's disease.

What's Happening With Cassava Sciences Stock?

There's nothing spectacular about the latest results for the company's flagship drug.

Is Cassava Sciences Back in the Game?

New York, New York--(Newsfile Corp. - September 27, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out...

NATIONALLY RANKED ROSEN LAW FIRM Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

Yalla Group

Zymergen

NEW YORK, NY / ACCESSWIRE / September 27, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

LAWSUITS FILED AGAINST ZY, YALA and SAVA - Jakubowitz Law Pursues Shareholders Claims

Boston, Massachusetts--(Newsfile Corp. - September 27, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?On August 24, 2021, after market hours, Cassava Sciences stock dropped over...

LAWSUIT FILED - Expanded Class Period: CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, have until October 26, 2021, to file a lead plaintiff motion.

(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Cassava Sciences Class Action Lawsuit

Live Ventures

Oatly

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

LAWSUITS FILED AGAINST OTLY, LIVE and SAVA - Jakubowitz Law Pursues Shareholders Claims

Ardelyx

Sesen Bio Inc.

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARDX, SESN and SAVA

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.

ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

Additional data is promising. But will investors trust it?

Why Shares of Cassava Sciences Rose 15% Today

San Francisco, California--(Newsfile Corp. - September 23, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions conc

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with Losses in Excess of $250,000 to Contact Firm's Attorneys Now, Securities Fraud Class Action Filed

Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

Radnor, Pennsylvania--(Newsfile Corp. - September 22, 2021) -   The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no later...

Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

Boston, Massachusetts--(Newsfile Corp. - September 22, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...

SAVA: Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. of Approaching Lead Plaintiff Deadline

On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares swang to a net intraday loss of about 3.52%, as of this writing, despite spiking more than 21% in the morning. The stock surged after the company posted top-line data on a pre-planned interim analysis of an ongoing open-label study with its drug label Simufilam in patients with […] The post Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?

Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?

Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off. The post SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?

SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?

Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease. Related Content:   Cassava CEO Goes Offensive Over Simufilam Data Allegations.

Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease

AUSTIN, Texas, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients with mild-to-moderate Alzheimer's disease.

Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer's Disease

New York, New York--(Newsfile Corp. - September 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Cassava Sciences, Inc. (SAVA) Investors and Encourages Investors to Contact the Firm Before October 26, 2021

SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.

News for Cassava Sciences Inc Stock (SAVA)